Table 3.
Odds ratios for inflammatory-related CpGs and pancreatic cancer risk identified in the nested case-control study, stratified by study and time to diagnosis
| cg05304729 | cg06192883 | |||
|---|---|---|---|---|
| Cases / Controls | Multivariate OR (95% CI)a | Cases / Controls | Multivariate OR (95% CI)a | |
| Among All Cohorts | ||||
| Q1 | 72 / 108 | ref. | 75 / 107 | ref. |
| Q2 | 93 / 107 | 1.37(0.90, 2.07) | 91 / 107 | 1.21(0.79, 1.83) |
| Q3 | 100 / 105 | 1.52(1.00, 2.31) | 84 / 106 | 1.12(0.73, 1.73) |
| Q4 | 125 / 108 | 1.92(1.27, 2.91) | 140 / 108 | 1.82(1.18, 2.78) |
| p for continuous = 0.002 | p for continuous = 0.008 | |||
| Among Time to Diagnosis ≤ 5 Years | ||||
| Q1 | 6 / 108 | ref. | 6 / 107 | ref. |
| Q2 | 12 / 107 | 2.15(0.75, 6.16) | 11 / 107 | 1.83(0.63, 5.33) |
| Q3 | 12 / 105 | 2.14(0.74, 6.17) | 12 / 106 | 1.80(0.62, 5.24) |
| Q4 | 20 / 108 | 3.37(1.23, 9.18) | 21 / 108 | 2.57(0.92, 7.21) |
| p for continuous = 0.02 | p for continuous = 0.09 | |||
| Among Time to diagnosis 5 – 10 Years | ||||
| Q1 | 11 / 108 | ref. | 15 / 107 | ref. |
| Q2 | 26 / 107 | 2.75(1.25, 6.07) | 23 / 107 | 1.68(0.79, 3.60) |
| Q3 | 18 / 105 | 2.27(0.97, 5.29) | 15 / 106 | 1.06(0.46, 2.45) |
| Q4 | 28 / 108 | 3.34(1.48, 7.54) | 30 / 108 | 1.87(0.85, 4.10) |
| p for continuous = 0.01 | p for continuous = 0.25 | |||
| Among Time to diagnosis > 10 Years | ||||
| Q1 | 51 / 108 | ref. | 51 / 107 | ref. |
| Q2 | 53 / 107 | 1.11(0.68, 1.79) | 55 / 107 | 1.08(0.67, 1.74) |
| Q3 | 66 / 105 | 1.38(0.85, 2.21) | 56 / 106 | 1.13(0.69, 1.86) |
| Q4 | 76 / 108 | 1.64(1.02, 2.64) | 84 / 108 | 1.67(1.03, 2.72) |
| p for continuous = 0.03 | p for continuous = 0.03 | |||
| Among NHSb | ||||
| Q1 | 44 / 49 | ref. | 35 / 49 | ref. |
| Q2 | 39 / 48 | 0.88(0.48, 1.63) | 32 / 48 | 0.82(0.43, 1.57) |
| Q3 | 45 / 48 | 1.07(0.58, 1.98) | 42 / 48 | 1.09(0.57, 2.06) |
| Q4 | 47 / 49 | 1.04(0.56, 1.96) | 66 / 49 | 1.53(0.80, 2.95) |
| p for continuous = 0.75 | p for continuous = 0.11 | |||
| Among HPFSb | ||||
| Q1 | 20 / 38 | ref. | 31 / 37 | ref. |
| Q2 | 32 / 37 | 1.79(0.86, 3.73) | 44 / 36 | 1.49(0.74, 3.01) |
| Q3 | 35 / 36 | 1.95(0.92, 4.11) | 26 / 37 | 0.82(0.38, 1.76) |
| Q4 | 57 / 37 | 3.44(1.67, 7.12) | 43 / 38 | 1.33(0.64, 2.77) |
| p for continuous <0.001 | p for continuous = 0.85 | |||
| Among PHSb | ||||
| Q1 | 9 / 22 | ref. | 7 / 22 | ref. |
| Q2 | 22 / 21 | 2.58(0.94, 7.11) | 20 / 21 | 3.49(1.16, 10.55) |
| Q3 | 19 / 21 | 2.49(0.89, 7.01) | 24 / 21 | 5.07(1.66, 15.47) |
| Q4 | 21 / 22 | 2.62(0.93, 7.36) | 20 / 22 | 3.65(1.20, 11.10) |
| p for continuous = 0.12 | p for continuous = 0.03 | |||
|
Replication in PanGenEUb,c | ||||
| Q1 | 50 / 71 | ref. | 72 / 71 | ref |
| Q2 | 77 / 71 | 1.49(0.9, 2.49) | 60 / 71 | 0.82(0.49, 1.35) |
| Q3 | 86 / 71 | 1.48(0.88, 2.48) | 94 / 71 | 1.23(0.77, 1.98) |
| Q4 | 126 / 72 | 2.08(1.22, 3.57) | 112 / 72 | 1.33(0.80, 2.21) |
| p for continuous = 0.01 | p for continuous = 0.11 | |||
a
Adjusted for age, date of blood draw, smoking and cell proportions, and cohorts for combined analyses.
b
Used study-specified quartiles for methylation level;
c
PanGenEU model adjustments include age, sex, smoking and cell proportions.